Array
(
[id] => 16597923
[patent_doc_number] => 20210024454
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-28
[patent_title] => NOVEL COMPOUND AND PHARMACETICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR METABOLIC SYNDROME COMPRISING THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/041960
[patent_app_country] => US
[patent_app_date] => 2019-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8972
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17041960
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/041960 | Compound and pharmaceutical composition for preventing or treating obesity or metabolic syndrome comprising thereof | Mar 25, 2019 | Issued |
Array
(
[id] => 17334537
[patent_doc_number] => 20220000868
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => NOVEL 4-CARBONYLAMINO-4-PHENYLPYRIMIDINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/297198
[patent_app_country] => US
[patent_app_date] => 2018-11-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7452
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17297198
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/297198 | 4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof | Nov 25, 2018 | Issued |
Array
(
[id] => 16718564
[patent_doc_number] => 20210085711
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-25
[patent_title] => USE OF FERRIC CITRATE IN PREVENTION AND/OR TREATMENT OF IRON-DEFICIENCY ANEMIA IN HYPERMENORRHEA PATIENT AND/OR PATIENT SUFFERING FROM HYPERMENORRHEA-ASSOCIATED GYNECOLOGIC DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/647994
[patent_app_country] => US
[patent_app_date] => 2018-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17160
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16647994
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/647994 | USE OF FERRIC CITRATE IN PREVENTION AND/OR TREATMENT OF IRON-DEFICIENCY ANEMIA IN HYPERMENORRHEA PATIENT AND/OR PATIENT SUFFERING FROM HYPERMENORRHEA-ASSOCIATED GYNECOLOGIC DISEASE | Sep 17, 2018 | Abandoned |
Array
(
[id] => 17141630
[patent_doc_number] => 20210309642
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => Process for Manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and Formulations Thereof
[patent_app_type] => utility
[patent_app_number] => 17/266075
[patent_app_country] => US
[patent_app_date] => 2018-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12589
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266075
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/266075 | Process for manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and formulations thereof | Aug 8, 2018 | Issued |